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Abstract: Neuropsychological assessment forms an essential part of the screen-
ing, diagnosis and general assessment of Alcohol-Related Brain Damage (ARBD). A 
number of studies have evaluated the applicability of various neuropsychological 
tests within the context of ARBD assessment, yet little attempt has been made to 
collate this evidence and discuss its clinical application. The aim of this protocol is to 
outline the methodology for a systematic review that aims to identify the neuropsy-
chological tools being used to assess cognitive impairments in individuals with ARBD 
and evaluate their efficacy within this context. We will search a number of online 
databases and other sources to identify studies using a neuropsychological tool in 
the screening, diagnosis or neuropsychological assessment of individuals with ARBD. 
Primary outcome measures of interest will be construct validity, convergent validity, 
reliability (retest and inter-rater), sensitivity, specificity, positive predictive value and 
practical considerations. Results from the review will assist clinicians and research-
ers involved in the assessment and diagnosis of ARBD by providing a synthesis and 
critical analysis of the evidence base for each tool, allowing them to make efficient 
and well-informed test selections. Review findings could also be used to inform the 
development of guidelines for ARBD diagnosis and assessment.
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1. Background
It is now well established that cognitive dysfunction is a sequel of long-term excessive alcohol con-
sumption (Brion, Pitel, Beaunieux, & Maurage, 2014; Harper, 2009; Oscar-Berman, 2012). Previously, 
the harmful effects of alcohol on the brain have been divided into distinct conditions including 
Wernicke’s encephalopathy (WE), Korsakoff’s syndrome (KS) and alcohol-related dementia (ARD). 
However, in order to reflect the heterogeneity in the presentation of alcohol-related disorders of 
cognition, the term alcohol-related brain damage (ARBD) has been used recently as an umbrella 
term to encompass the broad spectrum of brain damage associated with chronic alcohol consump-
tion (Ridley, Draper, & Withall, 2013). ARBD has been defined as a neuropsychiatric disorder charac-
terised by profound cognitive dysfunction linked to excessive alcohol consumption and allied 
thiamine (vitamin B1) deficiency, and includes WE, KS and ARD (Royal College of Psychiatrists, 2014).
While issues remain surrounding the nosology of ARBD (Ridley et al., 2013), impaired cognitive 
function represents a pervasive and debilitating feature of the disorder in all its presentations. 
Individuals with ARBD display impairments in episodic, semantic and implicit memory processes 
(Kopelman et al., 2009; Race & Verfaellie, 2012; Van Tilborg, Kessels, Kruijt, Wester, & Hulstijn, 2011) 
as well as deficits in executive functioning (Maharasingam, Macniven, & Mason, 2013; Van Oort & 
Kessels, 2009). As a corollary of this, neuropsychological assessment forms a vital part of the screen-
ing, diagnosis and general assessment of the condition (Kopelman, Thomson, Guerrini, & Marshall, 
2009; Wester, Westhoff, Kessels, & Egger, 2013).
For individuals with ARBD, neuropsychological assessment enables an understanding of both the 
nature and degree of cognitive impairment, as well as the functional implications of this (MacRae & 
Cox, 2003; Royal College of Psychiatrists, 2014). The outcomes of neuropsychological testing also 
have valuable implications for the selection of appropriate rehabilitation programmes and interven-
tions for individuals with brain damage (Vakil, 2012). Finally, assessments of cognitive function in 
those with ARBD may also provide useful measures of progress in response to treatment (Smith & 
Hillman, 1999). Yet, despite its cardinal role, current UK clinical guidelines (e.g. National Institute for 
Health & Clinical Excellence, 2011) offer no guidance on the neuropsychological assessment of 
ARBD. What is more, no standardised assessment battery exists for assessing cognitive impairment 
in individuals with ARBD, thus clinicians are reliant on non-specific measures.
The Royal College of Psychiatrists (2014) recommend the use of instruments such as the Montreal 
Cognitive Assessment, MoCA (Nasreddine et al., 2005) or the Addenbrook’s Cognitive Examination 
(Hsieh, Schubert, Hoon, Mioshi, & Hodges, 2013) to assess cognitive impairments in those with a his-
tory of long-term alcohol consumption. Others have suggested the Mini-Mental State Examination 
(MMSE; Folstein, Folstein, & McHugh, 1975) brief screening tool may be useful in hospital settings for 
measuring general cognitive function, though the tool’s limited ability to assess memory function is 
recognised (Kopelman et al., 2009). Extant research has examined the psychometric and practical 
merits of neuropsychological tools such as MoCA, MMSE and others in assessing alcohol-related 
cognitive impairment (e.g. Oudman et al., 2014; Wester, van Herten, Egger, & Kessels, 2013), yet lit-
tle attempt has been made to systematically collate and discuss the clinical application of this 
research. From a clinical perspective, this makes comparing the evidence base for each neuropsy-
chological tool difficult, complicating appropriate and prompt selection.
We outline a protocol here for a systematic review which will expand upon the understanding of 
the neuropsychological tools currently used in the assessment of ARBD and the efficacy of the iden-
tified tools in terms of assessing cognitive impairments in this population. Through an evidence-
based critical evaluation of the identified measures, our findings will be of benefit to clinicians and 
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researchers involved in the neuropsychological assessment of ARBD. Findings will also be of use 
from a health policy perspective, potentially informing the development of guidelines on the assess-
ment of the condition.
A similar review study has been published recently which systematically searched the literature 
relating to the comprehensive assessment of ARBD (including neuropsychological assessment; 
Horton, Duffy, Hollins Martin, & Martin, 2015), though further investigation is required for several 
reasons. Firstly, although published in 2015, Horton and colleagues conducted their literature search 
in June 2013. Since this time a number of studies have been published examining the psychometric 
properties of neuropsychological tools in the assessment of ARBD (e.g. Oudman et al., 2014; Wester, 
Roelofs, Egger, & Kessels, 2014). According to Horton and colleagues this form of study was scant at 
the time of their search, limiting their discussion. In addition, the review by Horton et al. contains 
several methodological and reporting weaknesses. Firstly, the authors do not report working from a 
protocol or registering the review methodology with an online database such as PROSPERO, making 
it difficult to establish the risk of bias involved in the review. Secondly, according to our preliminary 
literature search, Horton and colleagues appear to have missed several studies relating to neuropsy-
chological assessment which—according to their reported criteria—appear eligible for inclusion in 
their review (e.g. Borsutzky, Fujiwara, Brand, & Markowitsch, 2008; Crawford, Parker, & Besson, 1988). 
This is a particular issue as many of the relevant studies absent from Horton et al.’s review comment 
on the clinical efficacy of the assessments used (e.g. Brokate et al., 2003; O’Carroll, Moffoot, Ebmeier, 
& Goodwin, 1992). Thirdly, the authors only included studies with KS participants, excluding studies 
assessing ARD and ARBD and therefore omitting a significant body of valuable information regarding 
the neuropsychological assessment of ARBD. What is more, the authors stated in their inclusion 
criteria that they would only include participants diagnosed according to criteria outlined in the 
Diagnostic Statistical Manual-IV or the International Classification of Diseases-10, yet their included 
studies do not meet this criteria—suggesting inconsistencies between the reported methods and 
those employed in the review. Finally, their synthesis is largely descriptive, lacks critical evaluation of 
the neuropsychological tools and studies identified, and offers little advice on the clinical application 
of findings.
Combined, the issues with Horton and colleagues’ (2015) review potentially bias their conclusions 
and restrict their clinical application. It is anticipated that a more thorough review of the literature 
in this area, including studies focusing on participants with ARD and ARBD, would result in a review 
of substantially more studies (n = > 70) than the 17 included by Horton and colleagues. Consequently, 
further investigation of the literature on neuropsychological assessment of ARBD is warranted in 
order to provide a more comprehensive and contemporary understanding of both the tools used and 
their clinical utility.
1.1. Objectives
The planned review has two primary aims:
(1)  To systematically review the literature to identify the neuropsychological tools used in the 
screening, diagnosis and neuropsychological assessment of ARBD.
(2)  To evaluate the diagnostic, psychometric and practical merits of identified tools within the 
assessment of this population.
2. Methods
2.1. Protocol
In developing this protocol we consulted guidance on the conduct and reporting of protocols and 
narrative synthesis for systematic reviews, including the PRISMA-P guidelines (Moher et al., 2015), 
the PRISMA-P elaboration and explanation paper (Shamseer et al., 2015) and guidance on narrative 
synthesis provided by the Centre for Reviews and Dissemination (2009) and Popay et al. (2006). The 
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protocol is registered with the PROSPERO International Prospective Register of Systematic Reviews 
(Registration No. CRD42015030209).
2.2. Eligibility criteria
Studies will be selected according to the following predefined criteria.
2.2.1. Types of study design
We will include studies focusing on the neuropsychological assessment of ARBD and those using 
neuropsychological tools in the screening or diagnosis of the condition. Studies of interest include, 
but will not be restricted to, screening and diagnostic studies, cross-sectional and observational re-
search, epidemiology or prevalence studies, and case studies. Randomised control trials and treat-
ment studies will not be included as we have identified that these studies are less likely to comment 
on the psychometric or diagnostic properties of the tools used. Review studies will not be included. 
We will not apply any date or minimum sample size restrictions. Studies will not be confined to any 
geographical region. Only studies published in English and those in other languages that can be 
adequately translated to English using an online document translator will be included in the review. 
Both published and ongoing studies will be considered.
2.2.2. Types of participants/population
Included studies will focus on adult (18 years and older) human participants. Participants of interest 
are those being assessed for, or already diagnosed with, KS, ARD or ARBD. We will not include studies 
assessing cognitive impairment in WE participants due to the increased risk of alcohol intoxication 
obscuring performance on neuropsychological tests. Research focusing on KS participants who have 
developed the condition through non-alcohol-related means (such as non-alcohol associated thia-
mine depletion) will not be included. We will include studies where ARBD participants are assessed 
alongside controls, non-ARBD alcohol users and other clinical populations (e.g. those with 
dementia).
2.2.3. Types of assessments
Neuropsychological tools are defined as normatively-informed performance-based methods of 
measuring cognitive function (Harvey, 2012). Included studies will use at least one standardised 
neuropsychological assessment. Studies using only non-standardised neuropsychological measures 
will not be included. Neuropsychological tools may include brief screening measures, psychometric 
instruments, intelligence tests or computer-based cognitive assessments. Tools must be used to as-
sess cognitive impairment in individuals with ARBD or suspected ARBD as a form of screening, diag-
nosis or general assessment.
2.2.4. Types of outcome measures
We have consulted relevant research and guidance on the methodological and psychometric princi-
ples of neuropsychological testing (Pawlowski, Segabinazi, Wagner, & Bandeira, 2013; Strauss, 
Sherman, & Spreen, 2006; Willmes, 2010) and diagnostic measures (Parikh, Mathai, Parikh, Chandra 
Sekhar, & Thomas, 2008) in order to select a number of metrics as outcome measures. All primary 
and secondary outcome measures of interest and their definition are presented in Table 1. However, 
based on a preliminary search of the literature we have identified that many relevant studies do not 
report on these outcomes. Consequently, as we hope to identify the various neuropsychological as-
sessments being used with this population, we will not exclude studies if they do not report on any 
of our chosen outcome measures.
2.3. Information sources
We will search the following bibliographical databases: MEDLINE, Psych INFO, EMBASE, Science 
Direct, ProQuest Psychology Journals and Google Scholar. The reference lists of all included articles 
and of relevant reviews (e.g. Horton et al., 2015) will be searched for suitable studies. We will also 
engage in forward citation searches whereby articles which have cited our included studies will be 
identified and screened for relevance. To identify any relevant unpublished and/or ongoing studies 
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we will also contact academic and clinical experts within the field and search related grant council 
websites (e.g. Alcohol Research UK). We will not search clinical trial registers as research included 
within these databases is likely to focus on intervention efficacy as opposed to diagnosis or neu-
ropsychological assessment. Lastly, the complete list of included studies will be circulated to all 
authors to ensure all relevant literature is identified.
2.4. Search strategy
A draft search strategy was developed by all authors and subsequently peer-reviewed by the 
Specialist Unit for Review Evidence (SURE), a team of information specialist and systematic review-
ers with experience of designing and reviewing search strategies for systematic reviews. Separate 
search strategies will be employed for KS, ARD and ARBD. The review team has consulted Emtree 
and MeSH thesauruses, nosological systems, and engaged in group discussion to identify all relevant 
terms for each condition (e.g. “Korsakoff’s Syndrome, Korsakoff, Alcohol amnestic disorder”) and 
terms to identify studies relating to neuropsychological assessment (e.g. “screening”, “psychometric 
assessment”, “cognitive impairment”, “executive function”). Terms for each condition will be 
Table 1. Outcome measures of interest
Outcome measure Definition
Primary outcomes Construct validity Also known simply as “validity” or “test validity”, construct 
validity refers to the degree to which a test measures what it 
purports to measure 
Convergent validity A subset of construct validity (along with divergent validity) 
that refers to the degree to which scores on two different mea-
sures, which are theoretically assessing the same construct, 
correlate
Inter-rater reliability The correlation or consistency between the administration and 
scoring of the same test by two different examiners
Test–retest reliability Also known as “temporal reliability”, test–retest reliability refers 
to the correlation or consistency between scores for the same 
test administered at two points in time
Sensitivity & specificity Sensitivity: The ability of a test to correctly identify individuals 
with the condition of interest as impaired (i.e. true positives)
Specificity: The ability of a test to correctly identify individu-
als without the condition of interest as not impaired (i.e. true 
negatives)
Calculating sensitivity: True positive/true positive + false negative
Calculating specificity: True negative/true negative + false 
positive 
Positive predictive value The percentage of persons classed as impaired by a test who 
actually have the condition of interest
Calculating positive predictive value: True positive/ true posi-
tive + false positive
Practical considerations Refers to any practical factor which may affect the administra-
tion of the test, such as administration time, ease of admin-
istration, physical or psychological requirements of testing or 
cultural barriers to testing
Secondary outcomes Content validity The extent to which a test measures all aspects of the con-
struct it purports to and all items/questions are relevant to that 
construct
Face validity A face value, qualitative interpretation of the degree to which 
the test appears to measure the construct it aims to
Ecological validity The extent to which test scores are indicative of real life func-
tioning (e.g. the degree to which scores on a test of learning 
reflects the person’s ability to learn new information in day-to-
day life) 
Page 6 of 11
Heirene et al., Cogent Psychology (2016), 3: 1229841
http://dx.doi.org/10.1080/23311908.2016.1229841
combined with those relating to neuropsychological assessment using the Boolean operator “AND”. 
Language and publication date restrictions will not be applied. Treatment and review studies will be 
excluded from searches when possible. An example search strategy for KS-related evidence in the 
MEDLINE via EBSCO database can be found in Appendix 1. Strategies will be adapted for each data-
base according to their syntax codes and specificities.
2.5. Data management and selection process
The references and abstracts of all potentially relevant studies returned from the search strategy 
will be imported to EndNote reference management programme for duplicate removal. Following 
this, studies will be uploaded to Covidence, an online software program designed specifically for col-
lating and screening studies for systematic reviews. RH and GR-D will screen references and ab-
stracts via Covidence for relevance against two preliminary criteria:
(1)  The study participants are human adults (18 years or over)
(2)  The study uses, or appears to use, a neuropsychological tool to assess cognitive impairments 
associated with ARBD.
Full-text reports will be obtained for all studies which appear to meet the above criteria and for 
those which need further consideration before their inclusion or exclusion. Prior to screening full-
text reports, authors RH and GR-D will engage in a calibration process to enhance inter-reviewer 
consistency—screening 25 randomly selected studies. A Kappa statistic will be used to quantify 
agreement between researchers, with the aim of achieving a statistic >0.6 prior to beginning study 
selection (Viera & Garrett, 2005). RH and GR-D will then independently screen studies for eligibility 
via Covidence. Where necessary, additional information may be sought from study authors to facili-
tate decisions on study relevance. The rationale for all full-text exclusions will be documented using 
Covidence. Any disagreements arising from either phase of the selection process will be decided by 
authors BJ and PR. A PRISMA flow chart will be completed to display the process of study selection.
2.6. Data extraction
The abstraction of data from included studies will be carried out independently in duplicate by two 
authors (RH and BJ). This process will be guided by an extraction table designed by the authors ac-
cording to the specific aims of the review (see Additional file 2 for extraction table). Prior to extraction 
RH and BJ will independently pilot test the extraction table using five randomly selected included 
studies, subsequently reconvening to discuss the table’s comprehensiveness and consistency be-
tween reviewers. Disagreements arising from the extraction process will first be solved through dis-
cussion, then, if unresolved, via a third reviewer (GR or PR). In the event of missing or unclear data 
we will contact study authors to obtain further information.
We will abstract the following study details: authors, title, year, geographical region, study design, 
participant characteristics (sample size, age, gender, disease status, details of control and other 
groups), the neuropsychological assessment tool/s used and details of administration, any reference 
standard test used and any other assessment used concomitantly (e.g. alcohol screening tools). All 
quantitative and narrative data relating to the primary outcome measures of construct validity, 
convergent validity, test–retest and inter-rater reliability, sensitivity, specificity, positive predictive 
value and practical considerations will be abstracted. Any quantitative and narrative data authors 
provide regarding the secondary outcomes of content, face or ecological validity of tools will also be 
recorded. The definitions of all primary and secondary outcomes are included in the data extraction 
form to ensure consistency between reviewers.
2.7. Quality assessment
Following an examination of existing standardised quality appraisal checklists, such as those pro-
vided by the Critical Appraisal Skills Program or the QUADAS-2 diagnostic study checklist (Whiting et 
al., 2011), it was determined that no existing quality appraisal form met the specific requirements of 
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this review. Consequently, we have developed a checklist specifically for critically appraising studies 
using neuropsychological tools in the assessment ARBD (Table 2). In developing the checklist we 
consulted existing appraisal forms and guidance on factors which could potentially render the re-
sults of neuropsychological testing invalid (Evans, 2010).
The appraisal of studies using the checklist will be carried out independently by two review au-
thors (RH and BJ). Any disagreement will be resolved firstly through discussion, then through media-
tion by a third reviewer (GR-D or PR) if unresolved. Although we plan to assess the quality of evidence, 
we will not exclude studies of poor quality from the data synthesis. We wish to include all relevant 
studies using neuropsychological tools in the assessment of ARBD in order to enhance the knowl-
edge of the specific measures used and to assess their merit within this context. Nonetheless, we 
believe a measure of study rigour will be useful for the readers of the report in determining the qual-
ity of studies included. The results of the critical appraisal process will be displayed in tabular form 
and made available for readers of the final report. We will consider the impact of study quality on the 
strength of our findings.
2.8. Data synthesis
Based on the expected heterogeneity between studies and outcome measures, it is not expected 
that a meta-analysis will be appropriate for synthesising data from included studies. Therefore, a 
systematic narrative synthesis of findings will be provided. We have consulted guidance on narrative 
synthesis provided by Popay et al. (2006) who propose four key features of narrative synthesis: [1] 
developing a theory of how the intervention works, why and for whom, [2] developing a preliminary 
synthesis of findings in included studies, [3] exploring relationships in the data, and [4] assessing the 
robustness of the evidence. As our systematic review will focus on evaluating the efficacy of assess-
ment tools, as opposed to the efficacy of an intervention, we anticipate using only the latter three 
features to inform our narrative synthesis.
We will structure the review findings around the eight primary outcome measures: [1] construct 
validity, [2] convergent validity, [3] test–retest reliability, [4] inter-rater reliability [5, 6], sensitivity 
Table 2. Quality assessment checklist
Note: All questions to be answered in relation to the sample/s of focus (i.e. those with/being tested for ARBD).
* We define a reference standard for ARBD as a multifaceted approach to diagnosis involving at least two of the 
following: Comprehensive neuropsychological assessment, a review of medical history, clinical assessment, 
neuroimaging investigation.
# Estimations of pre-morbid intelligence may be achieved through specific neuropsychological tests known to be relatively 
immune to neurological damage (e.g. subscales of the Wechsler Adult Intelligence Scale IV; Wechsler, 2008) or via the 
collection of relevant demographic information (e.g. years of education and vocational achievement; Vakil, 2012).
Question Response
1. Was a sufficient period of abstinence (i.e. preferably >2 months 
but a minimum of >6 weeks) achieved prior to assessment? 
Yes/Can’t tell/No
2. Are participants diagnosed in accordance with (or already 
diagnosed using) the criteria outlined in nosological systems 
(DSM or ICD) or other accepted diagnostic criteria (e.g. Oslin & 
Cary, 2003)?
Yes/Can’t tell/No 
3. Is a diagnosis of ARBD confirmed using an appropriate reference 
standard* prior to or following neuropsychological assessment?
Yes/Can’t tell/No
4. Is the disease status of the participants clearly described? 
 (Including comorbidities such as depression & anxiety)
Yes/Can’t tell/No
5. Were persons with confounding conditions such as traumatic 
brain injuries or dementia excluded? 
Yes/Can’t tell/No
6. Was pre-morbid intelligence# taken into consideration when 
determining level of impairment? 
Yes/Can’t tell/No/Not appropriate 
7. Are the neuropsychological tools used specific to the language 
and culture of the population tested?
Yes/Can’t tell/No
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and specificity, [7] positive predictive value, and [8] practical considerations. We will also discuss 
additional findings relating to the content, face or ecological validity of tools, as well as the clinical 
application of findings. Finally, we will discuss the robustness of the evidence and the synthesis as 
per Popay and colleagues (2006) suggestions. Tables will also be used to support the data synthesis. 
The first table presented will display the details of all identified assessment tools (e.g. author, cogni-
tive domains assessed, format, diagnostic cut-off scores). A second table will present study findings 
relating to the validity, reliability, sensitivity and specificity statistics of each tool.
2.9. Amendments
If during the process of the systematic review any amendments are made to the methodology out-
lined in this protocol they will be recorded along with the date and the rationale. Any proposed 
methodological changes will be approved by all authors, with RH being responsible for documenting 
the process. Changes to the protocol methodology will be added to the PROSPERO registration and 
made available for readers of the final report. Changes will not be incorporated into the protocol.
3. Discussion
Alcohol-related brain damage is associated with a wide range of cognitive deficits. Accordingly, neu-
ropsychological assessment represents a key feature of the screening, diagnosis and general as-
sessment of the disorder. This systematic review will provide a synthesis of studies using 
neuropsychological instruments to assess cognitive impairment in individuals with ARBD, enhancing 
knowledge of the tools currently used. It will also critically evaluate the identified tools using a 
framework comprised of a number of pre-defined metrics. To our knowledge, this will be the first 
systematic review to specifically focus on the identification and evaluation of neuropsychological 
tools used with this population.
The present review will update and expand upon the existing review conducted by Horton et al. 
(2015) in several ways. Firstly, we will review studies focusing on participants with ARBD and ARD as 
well as KS, providing a novel synthesis and evaluation of the literature focusing on these popula-
tions. Secondly, screening and diagnostic studies, which were excluded by Horton and colleagues, 
will be included in the review in order to evaluate the use of specific neuropsychological tests within 
this context. Thirdly, we will employ a more thorough search strategy in order to identify relevant 
texts not included within the review by Horton et al. (2015). Overall, the current review will provide a 
more thorough and comprehensive investigation of the literature surrounding the neuropsychologi-
cal assessment of ARBD than that of Horton et al. (2015).
The findings of the review will be of benefit to clinicians and researchers involved in the neuropsy-
chological assessment of ABRD, providing a synthesis of the evidence underpinning the use of spe-
cific neuropsychological tools within various capacities, including diagnosis and the assessment of 
memory and executive function deficits. As stated by Strauss et al. (2006), identifying and critically 
reviewing the vast amount of literature pertaining to each neuropsychological test presents an al-
most impossible task for modern neuropsychologists. Thus, the findings of our review will enable 
clinicians and researchers to make informed, evidence-based decisions when selecting appropriate 
tests for ARBD assessment, without the time investment required to review the literature them-
selves. Our findings will also highlight gaps in the existing literature and directions for future re-
search. Finally, findings could also be used to inform the development of guidelines and policy 
relating to the assessment of ARBD.
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Example search strategy for MEDLINE via EBSCO
(1)  MEDLINE: TX (“Korsakoff’s Syndrome” or Korsakoff* or “Alcohol amnes* disorder” or “Alcohol-
induced amnestic disorder” or “Alcohol-induced persisting amnestic disorder”) AND TX 
(Neuropsychological [assess* or tool or evaluat* or screen* or diagnos* or measurement or 
test* or performance]); 283 results.
(2)  MEDLINE: TX (“Korsakoff’s Syndrome” or Korsakoff* or “Alcohol amnes* disorder” or “Alcohol-
induced amnestic disorder” or “Alcohol-induced persisting amnestic disorder”) AND TX 
(Cognitive [assess* or tool or evaluat* or screen* or diagnos* or measurement or test* or per-
formance]); 69 results.
(3)  MEDLINE: TX (“Korsakoff’s Syndrome” or Korsakoff* or “Alcohol amnes* disorder” or “Alcohol-
induced amnestic disorder” or “Alcohol-induced persisting amnestic disorder”) AND TX 
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(Psychometric [assess* or tool or evaluat* or screen* or diagnos* or measurement or test* or 
performance]); 11 results.
(4)  MEDLINE: TX (“Korsakoff’s Syndrome” or Korsakoff* or “Alcohol amnes* disorder” or “Alcohol-
induced amnestic disorder” or “Alcohol-induced persisting amnestic disorder”) AND TX 
(Assess* or evaluat* or screen*, diagnos* or measurement, test* or performance or prevalence 
sensitivity or specificity or predict* or validity or reliab* or impair* or memory or executive func-
tion* or frontal function* or amnesia* or intelligence or cognit* or dysfunction); 1,193 results.
(5)  MEDLINE: TX (“Korsakoff’s Syndrome” or Korsakoff* or “Alcohol amnes* disorder” or “Alcohol-
induced amnestic disorder” or “Alcohol-induced persisting amnestic disorder”) AND TX (“Mini-
Mental State Examination” or MMSE or “Rivermead Behavioural Memory Test” or RBMT or 
RBMT-3 or “Cambridge Neuropsychological Test Automated Battery” or CANTAB or 
“Addenbrooke’s cognitive examination” or ACE or ACE-R or “Montreal Cognitive Assessment” 
or MoCA or “Behavioural Assessment of the Dysexecutive Syndrome” or BADS or “Repeatable 
Battery for the Assessment of Neuropsychological Status” or RBANS or “Rey-Osterreith 
Complex figures task” or ROCF or “Wisconsin Card sorting test” or WCST or “Wechsler adult 
intelligence scale*” or WAIS* or “Wechsler test of adult reading” or WTAR* Rey Auditory Verbal 
Learning Test, RAVLT, The Delis-Kaplan Executive Function System, D-KEFS, Wechsler Memory 
Scale, WMS); 45 results.
